Cardiology
News
Empagliflozin cut PA pressures in heart failure patients
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time....
News
The socioeconomic revolving door of 30-day heart failure readmissions
Racial disparities in 30-day HF readmissions stem partly from variation in economic status of residential neighborhoods, regardless of hospital...
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
News
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against...
News
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
News
‘Cautious’ DOAC underdosing in AFib may push mortality higher
Risk-averse clinicians might be doing more harm than good by prescribing direct oral anticoagulants at lower-than-recommended dosages in hope of...
News
Observational study again suggests lasting impact of COVID-19 on heart
News
Many providers don’t follow hypertension guidelines
Most health care professionals rely on clinic BP measurements to make a new diagnosis of hypertension, and view pressure measured manually with a...
News
The earlier the better for colchicine post-MI: COLCOT
One substudy supported in-hospital initiation of colchicine and a second offered clues as to who may respond or experience tell-tale GI events.